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Although Pim-1 or Pim-2 can contribute to lymphoid transformation when overexpressed, 
the physiologic role of these kinases in the immune response is uncertain. We now report 
that T cells from Pim-1
 
 
 
/
 
 
 
Pim-2
 
 
 
/
 
 
 
 animals display an unexpected sensitivity to the 
immunosuppressant rapamycin. Cytokine-induced Pim-1 and Pim-2 promote the rapamycin-
resistant survival of lymphocytes. The endogenous function of the Pim kinases was not 
restricted to the regulation of cell survival. Like the rapamycin target TOR, the Pim kinases 
also contribute to the regulation of lymphocyte growth and proliferation. Although 
rapamycin has a minimal effect on wild-type T cell expansion in vitro and in vivo
 
,
 
 it 
completely suppresses the response of Pim-1
 
 
 
/
 
 
 
Pim-2
 
 
 
/
 
 
 
 cells. Thus, endogenous levels of 
the Pim kinases are required for T cells to mount an immune response in the presence of 
rapamycin. The existence of a rapamycin-insensitive pathway that regulates T cell growth 
and survival has important implications for understanding how rapamycin functions as an 
immunomodulatory drug and for the development of complementary immunotherapeutics.
 
The murine immune system maintains a pool
of lymphocytes that respond to antigenic chal-
lenge with rapid growth and proliferation.
Naive T cells compete in vivo for exogenous
factors including the cytokines IL-4 and IL-7
and for MHC-dependent proliferative signals
(1, 2). Once T cells encounter antigen, their
size increases dramatically (blastogenesis) as
they prepare for clonal expansion and the acqui-
sition of an effector phenotype (3). The ligation
of cytokine or antigen receptors promotes T
cell growth and survival in part by activating
the effector enzymes of the PI3K pathway, the
kinases Akt and TOR (4). Mice expressing an
activated Akt transgene have increased numbers
of peripheral T cells that manifest enhanced
resistance to apoptotic stimuli in vitro and this
effect correlates with the Akt-dependent ac-
tivation of TOR (5–7). T cells from Akt
transgenic mice are larger and show enhanced
proliferation in reponse to mitogens (8, 9).
However, Akt-deficient animals (10, 11) and
mice treated with the TOR inhibitor rapamy-
cin (12) mount a normal primary immune
response. These data suggest that alternate path-
ways exist that can promote lymphocyte growth
and survival in a PI3K/Akt/TOR-indepen-
dent manner.
IL-4, IL-7, IL-2, and TCR ligation activate
members of the signal transducers and activators
of transcription (STAT) family to promote ex-
pression of prosurvival molecules including the
Pim family of oncogenic serine/threonine
kinases. Pim-1, Pim-2, and Pim-3 are novel
components of the transcriptional response to
cytokine or antigen receptor ligation (13) and
their function is regulated primarily at the level
of expression (14). 
 
Pim-1
 
 and 
 
pim-2
 
 are ex-
pressed in most hematopoietic cells whereas
 
pim-3
 
 expression is highest in brain, kidney,
and mammary tissue (15). Several Pim targets
have been identified and include the proapop-
totic protein Bad (14, 16), members of the
suppressor of cytokine signaling (SOCS) family
(17, 18), the translational repressor eIF-4E
binding protein 1 (4E-BP1; 14) and the tran-
scription factor Myb (19). Pim-1 and Pim-2
transgenes can promote growth and survival of
hematopoietic cell lines (14, 17, 20).
We now report that Pim-1 and Pim-2 are
essential components of an endogenous path-
way that regulates T cell growth and survival.
Pim-1 up-regulation occurred rapidly after cy-
tokine treatment or mitogenic stimulation and
high levels of Pim-2 were observed several hours
later. T cells from Pim-1
 
 
 
/
 
 
 
Pim-2
 
 
 
/
 
 
 
 mice
responded to cytokine- or antigen receptor–
ligation comparably to cells from wild-type
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littermates. However, rapamycin treatment eliminated the
ability of IL-4 and IL-7 to promote the survival of Pim-1
 
 
 
/
 
 
 
Pim-2
 
 
 
/
 
 
 
 but not wild-type T cells. This correlated with the
failure of Pim-1
 
 
 
/
 
 
 
Pim-2
 
 
 
/
 
 
 
 T cells to maintain the phos-
phorylation-dependent inactivation of the Bcl-2–related
protein Bad in the presence of rapamycin. Rapamycin also
blocked the mitogen-induced activation of Pim-1
 
 
 
/
 
 
 
Pim-
2
 
 
 
/
 
 
 
 T cells at an early stage of blastogenesis before the up-
regulation of surface activation markers and cell cycle entry.
Pim deficiency enhanced the effect of rapamycin in vivo and
prevented superantigen-induced T cell activation and ex-
pansion. The identification of Pim-1 and Pim-2 as required
components of a rapamycin-insensitive pathway that regu-
lates lymphocyte growth and survival suggests that the Pim
kinases might serve as attractive targets for the development
of novel immunotherapeutic regimens.
 
RESULTS
Pim-1 and Pim-2 are induced by prosurvival signals
 
In contrast to most kinases implicated in T cell responses,
Pim-1 and Pim-2 were undetectable in nonstimulated T
cells. Pim-1 and Pim-2 expression was not observed in mu-
rine T cells ex vivo or after 12 h of culture without added
cytokine (Fig. 1 A). However, when the T cells were cul-
tured in the presence of IL-4 or IL-7, Pim-1 protein was de-
tected at 3 h and Pim-2 by 12 h. The dissimilarity in the ki-
netics of their expression suggested that Pim-1 and Pim-2
might play independent or sequential roles in the response to
prosurvival or proliferative signals. However, mice deficient
in Pim-1 (hereafter referred to as Pim-1
 
 
 
/
 
 
 
2
 
 
 
/
 
 
 
), Pim-2
(Pim-1
 
 
 
/
 
 
 
2
 
 
 
/
 
 
 
), or both kinases (Pim-1
 
 
 
/
 
 
 
2
 
 
 
/
 
 
 
) showed no
obvious differences when compared with Pim-1
 
 
 
/
 
 
 
2
 
 
 
/
 
 
 
 lit-
termates with respect to thymus size or thymocyte or pe-
ripheral T cell distribution (unpublished data) as described
previously by Mikkers et al. (15).
Given recent demonstrations that Pim transgenes can
promote cell survival, the response of T cells from Pim-1
 
 
 
/
 
 
 
2
 
 
 
/
 
 
 
 animals to the prosurvival cytokines IL-4 and IL-7
was examined. Splenic T cells from Pim-1
 
 
 
/
 
 
 
2
 
 
 
/
 
 
 
 or Pim-
1
 
 
 
/
 
 
 
2
 
 
 
/
 
 
 
 littermates cultured in vitro in the absence of
added cytokines showed identical survival kinetics (Fig. 1 B).
IL-4 and IL-7 addition strongly promoted T cell survival in
both Pim-1
 
 
 
/
 
 
 
2
 
 
 
/
 
 
 
 and Pim-1
 
 
 
/
 
 
 
2
 
 
 
/
 
 
 
 T cells. Thus, either
endogenous Pim-1 or Pim-2 play no role in the regulation
of T cell survival or alternate survival pathways are activated
by cytokine treatment.
IL-4 and IL-7 treatment of naive T cells also activated
the central antiapoptotic effector of the PI3K pathway, Akt,
as measured by the induction of Akt phosphorylation at
Serine 473 (Fig. 2 A). TOR is one key mediator of Akt-
dependent signal transduction (21). The TOR inhibitor ra-
pamycin can suppress Akt-dependent cell survival (14, 22).
Therefore, we examined the ability of rapamycin to affect T
cell viability after cytokine treatment. As one readout of
TOR activity, the phosphorylation status of the TOR sub-
strate p70 S6 kinase (p70S6K) and its primary target, the S6
ribosomal subunit, was first assessed. IL-4 or IL-7 addition
increased total p70S6K and S6 expression and phosphoryla-
tion relative to nonstimulated cells (Fig. 2 B). The addition
of rapamycin prevented cytokine-dependent p70S6K and S6
phosphorylation (Fig. 2 B). Despite this observation, rapa-
mycin had no effect on the ability of these cytokines to pro-
mote T cell viability (Fig. 2 C), suggesting that TOR might
also be dispensable for the T cell response to prosurvival cy-
tokines. The cytokine-dependent induction of Pim-1 and
Pim-2 by IL-4 or IL-7 was not affected by rapamycin treat-
ment (Fig. 2 D).
 
Endogenous levels of Pim-2 confer rapamycin-resistant 
T cell survival
 
IL-4 and IL-7 activate the Pim kinases and Akt/TOR but
neither pathway is absolutely required for cytokine-depen-
dent survival. Reasoning that the disruption of both path-
ways might have a more significant effect, we assessed
cytokine-induced survival in wild-type, Pim-1
 
 
 
/
 
 
 
2
 
 
 
/
 
 
 
, Pim-
1
 
 
 
/
 
 
 
2
 
 
 
/
 
 
 
, and Pim-1
 
 
 
/
 
 
 
2
 
 
 
/
 
 
 
 T cells treated with rapamycin.
Spontaneous apoptosis of T cells from all four genotypes was
Figure 1. IL-4– and IL-7–dependent survival is intact in Pim-deficient 
T cells. (A) C57BL/6 splenic T cells were cultured without cytokine ( ), 
with IL-4 ( ), or IL-7 ( ) for 3, 6, or 12 h (hr). Control was prepared from 
nonstimulated cells at the start of the culture period (0 h). Total cell lysates 
were serially probed for the expression of  -actin (Actin) as a loading con-
trol, Pim-1, or Pim-2 by Western blot. Due to alternative translational ini-
tiation, a single murine pim-1 transcript gives rise to two proteins of 34 
(bottom band) and 44 kD (top band). Murine pim-2 encodes three iso-
forms of 34 (bottom band), 37 (middle band), and 40 kD (top band). 
The results shown are representative of three independent experiments. 
(B) T cells from Pim-1 / 2 /  and Pim-1 / 2 /  littermates (key) were 
cultured without cytokine (None), IL-4 (  IL-4), or IL-7 (  IL-7) and the 
percent of viable cells measured daily for 4 d. Error bars represent standard 
deviation of the mean of triplicate samples. Results have been reproduced 
in five additional experiments. 
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suppressed by IL-4 or IL-7 (Fig. 3 A). Although rapamycin
had no effect on cytokine-dependent survival of wild-type
and Pim-1
 
 
 
/
 
 
 
2
 
 
 
/
 
 
 
 T cells, rapamycin treatment suppressed
the ability of T cells from Pim-1
 
 
 
/
 
 
 
2
 
 
 
/
 
 
 
 or Pim-1
 
 
 
/
 
 
 
2
 
 
 
/
 
 
 
mice to survive in response to IL-4 (Fig. 3 A). Pim-1
 
 
 
/
 
 
 
2
 
 
 
/
 
 
 
and Pim-1
 
 
 
/
 
 
 
2
 
 
 
/
 
 
 
 T cells also failed to survive in response
to IL-7 in the presence of rapamycin. These phenotypes
could not be explained by decreased IL-4 or IL-7 receptor
expression or increased levels of the death receptor Fas in ra-
pamycin-treated T cells relative to control Pim-1
 
 
 
/
 
 
 
2
 
 
 
/
 
 
 
 or
Pim-1
 
 
 
/
 
 
 
2
 
 
 
/
 
 
 
 T cells (unpublished data).
Cytokines promote cell survival in part by affecting the
expression and function of members of the Bcl-2 protein
family. Survival can be potentiated by enhanced Bcl-2 and
Bcl-x
 
L
 
 expression and their antiapoptotic function can be
suppressed by association with the BH3-only, proapoptotic
Figure 2. IL-4 and IL-7 promote rapamycin-independent survival. 
(A) Lysates were prepared from nonstimulated C57BL/6 T cells (0 h) or 
after 3 or 12 h of IL-4 ( ) or IL-7 ( ) treatment and serially probed for 
actin, Pim-1, Pim-2, phospho-Serine 473-Akt (pSer473 Akt), and Total Akt. 
Results shown were reproduced in four additional experiments. (B) C57BL/6 
T cells were preincubated in the presence ( ) or absence ( ) of 50 nM 
rapamycin (RAPA) for 1 h before stimulation with IL-4 ( ) or IL-7 ( ) for 
30 or 90 min. Control lysate was from nonstimulated T cells (time 0). 
Lysates were serially probed for actin, phospho-serine 371-p70 S6 Kinase 
(pSer371 p70S6K), Total p70S6K, phospho-Serine 235/Serine 236-S6 
(pSer235/236 S6), and Total S6 protein by Western blot. Results shown 
represent two experiments. (C) Viability was measured daily for 3 d in 
Pim-1 / 2 /  T cells cultured without treatment, cytokine   RAPA, or 
cytokine   RAPA (keys). (Top) IL-4. (Bottom) IL-7. Error bars represent 
standard deviation of the mean of triplicate samples and summarize six 
individual experiments. (D) Pim-1 and Pim-2 induction are rapamycin 
resistant. C57BL/6 T cells were stimulated with IL-4 ( ) or IL-7 ( ) in the 
presence ( ) or absence ( ) of 50 nM RAPA for 3 or 12 h. Control was 
prepared from nonstimulated T cells (time 0). Lysates were serially probed 
for actin, Pim-1, and Pim-2.
Figure 3. Pim-2 deficiency confers rapamycin sensitivity. (A) Viabil-
ity was measured daily for 3 d in splenic T cells from Pim-1 / 2 / , 
Pim-1 / 2 / , Pim-1 / 2 / , and Pim-1 / 2 /  littermates cultured 
without cytokine (None),   IL-4, or   IL-7 in the presence ( ) or absence 
( ) of 25 nM RAPA (key). Error bars represent standard deviation of the 
mean of triplicate samples. Data have been reproduced in eight addi-
tional experiments. (B) T cells from female Pim-1 / 2 /  and Pim-1 / 2 /  
littermates were stimulated with IL-7 ( ) in the presence ( ) or absence 
( ) of 50 nM RAPA and lysates prepared at 1/2 and 12 h. Control was 
from nonstimulated cells prepared at the start of the experiment (0 h). 
Lysates were serially probed for the expression of actin, Bcl-2, Bcl-xL, Bim, 
Bad, phospho-serine 136 Bad (pSer136 Bad), and phospho-serine 112 Bad 
(pSer112 Bad). For Bim, the upper band corresponds to BimEL at  23 kD 
and the lower to BimL at 16 kD. Results have been reproduced in three 
independent experiments.THE PIM KINASES CONFER RAPAMYCIN RESISTANCE | Fox et al. 262
proteins Bim and Bad (2). High levels of Bcl-2, Bcl-xL, Bim,
and Bad were evident in IL-7–treated Pim-1 / 2 /  and
Pim-1 / 2 /  T cells in the presence and absence of rapa-
mycin (Fig. 3 B). The proapoptotic function of Bad can be
suppressed by its phosphorylation at multiple residues in-
cluding serines 112 (Ser112) and Ser136 (23). The pattern of
Bad phosphorylation at Ser136 in response to IL-7 and ra-
pamycin treatment was identical when Pim-1 / 2 /  were
Figure 4. The Pim kinases confer rapamycin-resistant T cell blasto-
genesis. (A) C57BL/6 splenic T cells were activated by  CD3/ CD28 and 
lysates were prepared after 0, 1/2, 1, 2, 3, 6, and 12 h of stimulation and 
serially probed for the expression of actin, Pim-1, and Pim-2 proteins by 
Western blot. (B) Activation-induced p70S6K and S6 phosphorylation is 
rapamycin sensitive. C57BL/6 splenic T cells were preincubated for 1 h in 
the presence ( ) or absence ( ) of 50 nM RAPA and activated with  CD3/
 CD28 for 0, 10, and 30 min. Lysates were probed for actin, phospho-serine 
371-p70 S6 kinase (pSer371 p70S6K), total p70S6K, phospho-serine 235/
serine 236-S6 (pSer235/236 S6), and total S6 expression. (C) In the experi-
ments described in B, Western blots were also performed with lysates 
from rapamycin-treated and control cells after 3 and 12 h of activation 
and probed for actin, Pim-1, and Pim-2 expression. (D) Splenic T cells from 
Pim-1 / 2 / , Pim-1 / 2 / , Pim-1 / 2 / , and Pim-1 / 2 /  mice 
were activated by  CD3/ CD28 in the absence ( ) or presence ( ) of 
25 nM RAPA (key). Control cells were cultured with  CD28 only ( CD28). 
After 2 d of culture, forward scatter, and surface CD69, CD25, and CD62L 
expression was assessed. (E) Cell cycle was assessed in the Pim-1 / 2 /  
and Pim-1 / 2 /  T cells described in D by BrdU incorporation analysis. 
The percentage of cells in the G1 (2N-PI BrdU ; bottom left), S (PI BrdU ; 
top), and G2M (4N-PI BrdU ; bottom right) phases of the cell cycle is 
shown (insets). Results shown are representative of six experiments. 
(F)5-(and 6-)carboxyfluorescein diacetate, succinimidyl ester–labeled in-
put T cells from Pim-1 / 2 /  or Pim-1 / 2 /  mice were activated for 
4 d in the presence ( ) or absence ( ) of 25 nM RAPA. Control cells were 
cultured with  CD28 only for 2 d ( CD28) and showed no decay in 
fluorescence relative to input cells at day 0. Numbers above the leftmost 
brackets represent the percent of cells that had divided more than three 
generations. For Pim-1 / 2 /  cells, the majority of the input population 
failed to divide (*). Data are representative of three experiments.JEM VOL. 201, January 17, 2005 263
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compared with Pim-1 / 2 /  T cells (Fig. 3 B). A dissimilar
pattern of Ser112 phosphorylation was observed. Whereas
IL-7–induced Ser136 phosphorylation was detected after 30
min of cytokine treatment, Bad phosphorylation at Ser112
was not observed until 12 h. This pattern overlapped with
that of Pim-2 induction in response to IL-7 (Figs. 1 A and 2
D). Further, IL-7–induced Ser112 phosphorylation was re-
sistant to rapamycin in Pim-1 / 2 /  T cells but not in
Pim-1 / 2 /  cells (Fig. 3 B). Thus, the Pim kinases con-
tribute to the regulation of cell survival in part through regu-
lating the phosphorylation of Bad.
The Pim kinases are required for rapamycin-resistant 
T cell activation
In addition to its role in Akt-dependent cell survival (22),
TOR is considered a critical regulator of protein translation
and cell growth (24). Since CD28 ligation has been reported
to activate Akt in T cells and might therefore promote
TOR-dependent translation (25), we examined the relative
contributions of endogenous Pim-1, Pim-2 and TOR to T
cell growth after mitogenic stimulation with anti-CD3/anti-
CD28 antibodies ( CD3/ CD28).  CD3/ CD28 treat-
ment induced a pronounced increase in p70S6K and S6
phosphorylation that could be suppressed by rapamycin (Fig.
4 B).  CD3/ CD28 treatment up-regulated Pim-1 expres-
sion in T cells within 30 min and Pim-2 by  12 h (Fig. 4
A). Activation-induced Pim kinase expression was rapamy-
cin resistant (Fig. 4 C).
T cells increase in size before their entry into the S phase
of the cell cycle. Consistent with this, the mean forward
scatter of T cells had more than doubled 2 d after  CD3/
 CD28 treatment (Fig. 4 D). Blastogenesis was accompanied
by increased surface expression of the activation markers
CD69 and CD25 and CD62L down-regulation. All of these
parameters were nearly identical when  CD3/ CD28-
treated T cells from Pim-1 / 2 / , Pim-1 / 2 / , Pim-1 /  
2 / , or Pim-1 / 2 /  mice were compared (Fig. 4 D). Ra-
pamycin had little effect on  CD3/ CD28-induced blasto-
genesis and CD69 or CD62L expression in Pim-1 / 2 /  or
Pim-1 / 2 /  T cells (Fig. 4 D) even when added at 200
nM (unpublished data). In contrast, rapamycin treatment
suppressed  CD3/ CD28-induced blastogenesis in Pim-1 / 
2 /  T cells and completely prevented activation-induced
blastogenesis in Pim-1 / 2 /  T cells. Pim-1 / 2 /  T cells
also failed to up-regulate surface CD69 and CD25 expres-
sion and decrease CD62L when stimulated by  CD3/
 CD28 in the presence of rapamycin. For both Pim-1 / 
2 /  and Pim-1 / 2 /  T cells, the addition of IL-2 had no
effect on the rapamycin-dependent suppression of cell
growth (unpublished data).
In the absence of stimulation,  98% of T cells were in
the G0/G1 phase of the cell cycle as assessed by bromo-deoxy-
uridine (BrdU) incorporation (Fig. 4 E) and did not prolifer-
ate in culture (Fig. 4 F). After 2 d of  CD3/ CD28 treat-
ment, Pim-1 / 2 /  T cells were distributed across the cell
cycle with approximately one-third of the population in
each of G1, S, or G2M phases. At 4 d, all input Pim-1 / 2 / 
T cells had divided at least once and 45% of the population
had undergone three or more rounds of division (Fig. 4 F).
Both rapamycin treatment and Pim deficiency alone had
modest effects on cell cycle entry and proliferation after
 CD3/ CD28 treatment relative to control. However, the
combined effect of suppressing both pathways was striking.
No T cells derived from Pim-1 / 2 /  mice had entered
the S phase of the cell cycle 2 d after  CD3/ CD28 treat-
ment in the presence of rapamycin (Fig. 4 E). Close to 90% of
input Pim-1 / 2 /  T cells failed to divide in the presence of
rapamycin even 4 d after  CD3/ CD28 stimulation (Fig. 4 F).
Pim kinase deficiency enhances rapamycin action in vivo
The deletion of Pim-1 and Pim-2 sensitized T cells to TOR
inhibition in vitro. This raised the possibility that the in vivo
immunosuppressive action of rapamycin might be enhanced
in Pim-deficient animals. Superantigens such as the toxic
shock syndrome toxin (TSST) have been widely used to
study activation and proliferation of T cells in vivo. Both
Pim-1 / 2 /  and Pim-1 / 2 /  animals treated with
TSST for 2 d contained sixfold more CD25  T cells (Fig. 5
A) and a higher proportion of TSST-reactive V 3  cells
(Fig. 5 B) relative to vehicle-treated littermates. In Pim-1 / 
2 /  animals, rapamycin did not affect these parameters. In
contrast, rapamycin treatment of Pim-1 / 2 /  mice sup-
pressed TSST-induced T cell activation (Fig. 5 A). Further,
Figure 5. Pim-1 and Pim-2 are required for rapamycin-resistant 
T cell expansion and activation in vivo. (A) 6–8-wk-old Pim-1 / 2 /  
or Pim-1 / 2 /  mice (key) were pretreated with RAPA (  RAPA) or no 
drug (  RAPA) before TSST (  TSST) or vehicle (  TSST) injection. The per-
cent of CD25  peripheral T cells (gated on live Thy1  cells) is shown. Error 
bars represent the standard error from the mean of 3 to 12 individuals in 
each group. (B) The percent of the T cells described in A that were positive 
for TCR V 3 is also shown.THE PIM KINASES CONFER RAPAMYCIN RESISTANCE | Fox et al. 264
V 3  T cell expansion was completely suppressed by rapa-
mycin in TSST-treated Pim-1 / 2 /  mice (Fig. 5 B).
DISCUSSION
We report that Pim-1 and Pim-2 are regulators of rapamycin
sensitivity in T cells. Although mature T cells developed
normally in Pim-deficient animals, T cells from Pim-1 / 
2 /  and Pim-1 / 2 /  mice were unable to respond to
prosurvival cytokines in the presence of the drug. The data
suggest that endogenous Pim-2 is the primary mediator of
rapamycin-resistant cell survival and that Pim-1 expression
alone is insufficient to promote prolonged rapamycin-resis-
tant survival. Rapamycin also blocked  CD3/ CD28-
induced T cell activation at early blastogenesis before cell cycle
entry in Pim-1 / 2 /  but not wild-type T cells. Despite its
clinical use in delaying transplant rejection, the precise basis
by which rapamycin functions as an immunosuppressant is
unclear. This report suggests that rapamycin does not inhibit
T cell growth, proliferation or survival because endogenous
Pim-1 and Pim-2 can maintain the survival and growth of
rapamycin-treated T cells. Therefore, despite the established
clinical efficacy of rapamycin, it remains at best a partial im-
munosuppressant in vivo and in vitro. Complete immuno-
suppression requires the concomitant inhibition of Pim ki-
nase activity.
Our work suggests that endogenous Pim kinase expres-
sion is an important determinant of rapamycin sensitivity.
The data help to explain some of the confusing results that
have been reported concerning the effect of rapamycin treat-
ment in lymphocyte activation and survival. Although rapa-
mycin was originally described as an inhibitor of cell prolif-
eration that acts by inducing arrest at the G1 phase of the cell
cycle (26), subsequent data suggest that its antiproliferative
effects may be stimulus or cell type specific. For example, ra-
pamycin treatment can cause thymic atrophy in mice and
rats (27–29). However, rapamycin has only a modest effect
on the survival of peripheral T cells in vivo (29). In activated
T cells, rapamycin has been reported to inhibit IL-2R up-
regulation and IL-2–dependent proliferation in some studies
(26, 30–32) but not others (33–35). Recent work suggests
that while some CD4-dependent immune responses are ra-
pamycin sensitive (36, 37), CD8  T cell function is largely
rapamycin resistant (29, 36, 38, 39). It is tempting to specu-
late that the Pim kinases might account for the residual im-
mune function observed in the presence of rapamycin in
these studies.
Pim-1 and Pim-2 do not contribute equally to the phe-
notypes we have observed. Pim-2 was induced much later
than Pim-1 and appeared to play a more substantial role in
the regulation of cytokine and mitogen-induced survival
and growth. Nevertheless, endogenous Pim-1 does appear to
partially compensate for Pim-2 deficiency in mitogen-
induced T cell growth. Because the combined deficiency of
Pim-1 and Pim-2 eliminated cytokine-dependent cell sur-
vival and  CD3/ CD28- and superantigen-induced T cell
activation in the presence of rapamycin, Pim-3 seems un-
likely to contribute to the rapamycin-insensitive growth of
T lymphocytes. Recently, animals deficient in all three Pim
kinases have been reported. Although these mice show re-
duced body size, their lymphocytes display only mild defects
in cytokine-induced proliferation (15).
The molecular basis of Pim kinase–dependent lympho-
cyte survival is explained in part through regulation of the
proapoptotic Bcl-2–related protein Bad. Pim-2–deficient T
cells die subsequent to prosurvival cytokine treatment in the
presence of rapamycin despite continued Bcl-2 and Bcl-xL
expression. It is well appreciated that Bcl-2 and Bcl-xL func-
tion are antagonized in part by their heterodimerization with
Bad and that this interaction is controlled by Bad phosphor-
ylation at multiple residues, including Ser112, Ser136, and
Ser155 (23). Phosphorylated Bad is retained in the cytoplasm
by the 14-3-3 proteins (23). The relative roles played by
each of these residues in regulating the ability of Bad to an-
tagonize Bcl-2 and Bcl-xL function remains controversial.
Many studies suggest that Akt is one of the primary kinases
that phosphorylates Bad at Ser136 (40, 41), in part because
Ser136 phosphorylation is sensitive to PI3K inhibitors (41,
42). Another group has reported that the kinetics of Ser112
and Ser136 phosphorylation in response to IL-7 treatment
differ and that only the former occurs in a PI3K-indepen-
dent manner (42). Recently, Chiang et al. showed that the
PP2A-dependent dephosphorylation of Bad at Ser112 is re-
quired for Ser136 dephosphorylation, the dissociation of Bad
from 14–3-3, and apoptosis (43). The authors proposed that
Ser112 served as the “gatekeeper” of Bad function. Al-
though kinases in addition to Pim-2 can phosphorylate Bad
at Ser112 in vitro (41, 44, 45), the present data suggests that
Pim-2 plays a primary role in regulating Bad phosphoryla-
tion at Ser112 in T cells.
In summary, Pim kinase deficiency greatly enhances the
immunosuppressive action of rapamycin in vivo and in vitro.
Thus, inhibitors of the Pim kinases in combination with ra-
pamycin would be expected to induce a greater degree of
immunosuppression as compared with either drug alone.
Analogous to the rapamycin-dependent inhibition of TOR,
the pharmacological inhibition of the Pim kinases might
have immunomodulatory benefits on its own. The observa-
tion that the germline deletion of Pim-1 and Pim-2 has a
modest phenotype outside of the hematopoietic system and
that, aside from its effects on T cells, rapamycin is tolerated
well in Pim-1 / 2 /  animals, suggests that these possibili-
ties should be explored.
MATERIALS AND METHODS
Mice.  Pim-1 / 2 / , Pim-1 / 2 / , Pim-1 / 2 / , and Pim-1 / 2 / 
animals were generated from Pim-1 / Pim-2 /  mice, a gift of Paul Roth-
man, Columbia University, New York, NY) (17). Genotyping by PCR
with tail snip DNA was performed as described previously (17). C57BL/6
mice were purchased from Jackson ImmunoReasearch Laboratories. Unless
otherwise indicated, all experiments were performed on male littermates at
4 to 10 wk of age. In all experiments, mice were injected IP. Mice were
bred and maintained at the University of Pennsylvania in accordance with
the Institutional Animal Care and Use Committee guidelines.JEM VOL. 201, January 17, 2005 265
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Antibodies and Western blots.  Mouse anti–Pim-2 1D12, mouse anti–
Pim-1 19F7, and goat anti–actin I-19, and goat anti–mouse IgG, bovine
anti–goat IgG, and goat anti–rabbit IgG coupled to horseradish peroxidase
were purchased from Santa Cruz (Santa Cruz Biotechnology, Inc.). Hamster
anti–mouse Bcl-2 3F11, rabbit anti–mouse Bim, and anti-hamster IgG–
HRP were purchased from BD Biosciences. Rabbit anti–mouse phospho-
serine 371 p70S6K, rabbit anti–mouse phospho-Ser235/Ser236 S6 riboso-
mal protein, rabbit anti-phospho Ser473 Akt, rabbit anti-phospho Ser136
Bad, rabbit anti-phospho Ser112 Bad, rabbit anti-phospho Ser155 Bad, rab-
bit anti-S6 ribosomal protein, rabbit anti-Akt, and rabbit anti-Bad were
purchased from Cell Signaling. Preparation and quantitation of whole cell
extracts lysed in PBS   1% NP-40 supplemented with protease (Roche)
and phosphatase inhibitor cocktails I and II (both from Sigma-Aldrich) and
Western blotting as described previously in detail (14). 50–100  g of pro-
tein was resolved on a 4–12% or 10% NuPage bis-tris polyacrylamide gels
and transferred to nitrocellulose as directed (Invitrogen). Blots were blocked
in PBS containing 10% milk and 0.2% Tween-20 (both from GIBCO
BRL), incubated in primary antibody in 5% milk overnight at 4 C and
washed several times for 15 min each in PBS   0.2% Tween. Target pro-
tein was visualized by incubation with a species appropriate HRP-conju-
gated secondary antibody at room temperature for 1 h and ECL-Advance
chemiluminescent reagent (Amersham Bioscience). For serial Western blot-
ting, membranes were stripped by incubating for 30 min at 65 C in PBS  
1% SDS and 100  M  -mercaptoethanol followed by six washes in PBS  
0.2% Tween-20.
Thymocyte and T cell preparation, activation, and flow cytometric
analyses.  Thymuses and spleens were pooled from three to five animals.
Live thymocytes were enriched by Ficoll centrifugation as directed by the
manufacturer (Amersham Biosciences) and then resuspended at 106/ml in
DMEM supplemented with 10% FCS, penicillin/streptomycin/fungizone,
100   M   -mercaptoethanol, 2 mM L-glutamine, 100  M nonessential
amino acids, and 10 mM Hepes buffer (all from GIBCO BRL). Flow cyto-
metric analysis of thymocytes was performed using a FACSCalibur (BD
Biosciences) and FITC rat anti–mouse Thy1.2 53–2.1 or FITC anti–rat
Thy1.1 OX-7, PE anti–mouse CD4 L3T4 and APC anti–mouse CD8a
53.6–7 antibodies (all from BD Biosciences). Total thymocyte numbers
were calculated by Trypan blue exclusion. Splenic T cells were enriched to
 95% purity (as assessed by staining with PE rat anti–mouse Thy1.2 30-
H12 or PE anti–rat Thy1.1 OX-7 antibodies) using the StemStep T Cell
Purification kit as directed by the manufacturer (Stem Cell Technologies
Inc.). Lysates were then immediately prepared from a fraction of each thy-
mocyte or T cell preparation (time 0). In some Western blotting experi-
ments, half of each cell preparation was preincubated in 50 nM of rapamy-
cin (Sigma-Aldrich) dissolved in methanol, or the vehicle control, for 1 h at
37 C before addition of cytokines or in vitro activation. For some flow cy-
tometric analyses, T cells were preincubated in 25 nM rapamycin or vehicle
in an identical manner and fresh rapamycin was added at day 2 of the exper-
iment. For cytokine treatment of naive T cells, cells were cultured at 5  
106/ml in vitro with the addition of 10 ng/ml of recombinant mouse IL-4
or 10 ng/ml of recombinant mouse IL-7 (both from BD Biosciences) for
the times indicated. Viability was assessed daily by flow cytometric analysis
of the exclusion of propidium iodide (PI). Flow cytometric analysis was also
performed with FITC Thy1.1 or Thy1.2, biotin hamster anti–mouse Fas
Jo.2, PE rat anti–mouse IL-7R SB/199, rat anti–mouse IL-4R mIL4R-M1,
and FITC rat anti–mouse IgG (all from BD Biosciences). Another set of
cells were activated in one of two ways, either by the addition of 10 ng/ml
PMA and 250 ng/ml ionomycin (both from Sigma-Aldrich) or by anti-
body-mediated TCR and CD28 cross-linking as follows: 24 well plates
were preincubated at 4 C overnight with 1  g/ml of both anti-Armenian
and anti-Syrian Hamster IgG antibodies (Jackson ImmunoResearch Labora-
tories, Inc.) in PBS, washed three times in PBS and then incubated with 1
 g/ml hamster anti–mouse CD3  145-2C11 and 2  g/ml hamster anti–
mouse CD28 37.51 in PBS at 37 C for 1 h and cells added at 5   106/ml.
Control cells were cultured in an identical manner except anti-CD3 was
omitted from the culture preparation. For T cell activation studies, live cells
were enriched by Ficoll centrifugation after 2 d of culture and activation
status was assessed via analysis of mean forward scatter and using FITC anti–
mouse CD69 H1.2F3, APC rat anti–mouse CD25 PC61, and PE anti–
mouse CD62L MEL-14 (all antibodies from BD Biosciences). A fraction of
each preparation was also resuspended in medium and incubated for 2 h at
37 C with 10  M BrdU (Calbiochem). Cells were then fixed in cold 70%
ethanol and stained with mouse anti-BrdU 3D4 and FITC rat anti–mouse
IgG (both antibodies from BD Biosciences) according to the manufacturer’s
protocol and resuspended in PI   1  g/ml RNase A before FACS analysis.
In a series of parallel experiments, T cells were suspended in PBS and la-
beled after a 5-min incubation with 5  M 5-(and 6-)carboxyfluorescein di-
acetate, succinimidyl ester (Molecular Probes) as directed by the manufac-
turer and then activated by TCR and CD28 cross-linking in the presence of
50 nM rapamycin. Fresh rapamycin or vehicle was added at day 2 of cul-
ture. In some cases, recombinant murine IL-2 (BD Biosciences) was added.
In vivo rapamycin and superantigen treatment. For assessment of to-
tal thymocyte numbers, animals were given daily doses for 3 d of 3 mg/kg
rapamycin in water. Animals were then killed and total thymocytes counted
by Trypan blue exclusion. Control animals were given water only. For the
superantigen-induced activation experiments, animals were treated with
3 mg/kg rapamycin daily for 3 d. On day 2, mice were given 50 mg of
D-galactosamine hydrochloride (Sigma-Aldrich) in PBS, followed by 100  g
of TSST (Sigma-Aldrich) in PBS 30 to 60 min later. On day 4, spleen and
LN cells from individual animals were pooled, live lymphocytes enriched
by Ficoll centrifugation, and then assessed by flow cytometric analysis with
PE anti-Thy1, APC anti-CD25, biotinylated anti–mouse V 3 T cell recep-
tor KJ25, anti–mouse V 4 KT4, anti–mouse V 7 TR10, and anti–mouse
V 11 RR3-15 antibodies, and then FITC–streptavidin (all antibodies from
BD Biosciences).
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